Inhibition of LKKR2 may rescue neurons that are dying due to a type of Parkinson’s disease that is caused by a single genetic ...

Putting the brakes on an enzyme might rescue neurons that are dying due to a type of Parkinson's disease that's caused by a ...

The results of experiments in mice models were "astounding," said biochemist Suzanne Pfeffer of Stanford University.

Hearing impairment linked to Parkinson’s disease risk The scientists focused on how COMMD3, a key Commander protein, affects the lysosome. When this gene was removed from cells, GCase levels ...

Parkinson’s disease (PD) is one of the most common progressive neurodegenerative pathologies that leads to dopaminergic deficiency and motor manifestations. Alpha-synuclein aggregation is a ...

Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech ...

Therefore, we evaluated the effects of the compounds on the mTOR pathway. We examined whether the six compounds modulated mTORC1 activity by regulating lysosomal positioning. This was accomplished by ...

Genetic and pharmacologic targeting of the PTEN/PI3K/AKT/mTOR signaling pathway was used as a potential therapeutic strategy in the peripheral neuropathies Hereditary Neuropathy with ... (HNPP).

Treating the genetically engineered mice with rapamycin, a drug that targets mTOR, not only prevented excessive protein production in mice with a condition like Parkinson's disease, but also eased ...

A so-called pathological protein long associated with Parkinson’s disease has been found in a new study to trigger cells to increase protein synthesis, an event that eventually kills the ...

Treating the genetically engineered mice with rapamycin, a drug that targets mTOR, not only prevented excessive protein production in mice with a condition like Parkinson’s disease, but also eased ...